|
Jul 18
|
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
|
|
Jul 17
|
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
|
|
Jul 16
|
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice
|
|
Jul 16
|
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
|
|
Jul 15
|
Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know
|
|
Jul 15
|
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)
|
|
Jul 11
|
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
|
|
May 29
|
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
|
|
May 27
|
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT
|